Kornimate/medical-research-clean huggingface dataset:
dapagliflozin effect on symptoms and biomarkers in patients with heart failure

Conditions: Chronic Heart Failure With Reduced Systolic Function

Summary: the primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure disease-specific biomarkers, symptoms, health status, and quality of life in patients with chronic heart failure with reduced systolic function.

a 12-week randomized, double-blind, placebo-controlled trial to evaluate the effects of once-daily dapagliflozin 10 mg on heart failure disease-specific biomarkers (bnp and ntprobnp), symptoms, health status, and quality of life in patients with chronic heart failure with reduced systolic function.

Eligibility criteria:
inclusion criteria: 1. established diagnosis of new york heart association (nyha) class ii or class iii heart failure (left ventricular ejection fraction ≤40% due to either ischemic or non-ischemic etiology) with reduced systolic function for at least 16 weeks prior to enrollment 2. no change in diuretic management for at least 1 week prior to enrollment 3. brain natriuretic peptide (bnp) ≥100 pg/ml and/or n-terminal pro b-type natriuretic peptide (ntprobnp) ≥ 400 pg/ml at enrollment exclusion criteria: 1. history of type 1 diabetes 2. estimated glomerular filtration rate (egfr) \< 30 at enrollment 3. hospitalization for heart failure within the 30 days prior to enrollment 4. admission for an acute coronary syndrome (st-elevation myocardial infarction, non-st-elevation myocardial infarction, or unstable angina), percutaneous coronary intervention, or cardiac surgery within the 30 days prior to enrollment 5. admission for cardiac resynchronization therapy (crt) within 90 days prior to the screening visit 6. planned cardiovascular revascularization (percutaneous intervention or surgical) or major cardiac surgery (coronary artery bypass grafting, valve replacement, ventricular assist device, cardiac transplantation, or any other surgery requiring thoracotomy) within the 90 days after enrollment 7. patients who are volume depleted based upon physical examination at the time of screening or randomization

Keywords: heart failure dapagliflozin sodium-glucose co-transporter-2 (sglt-2) inhibitors
family cognitive behavioral therapy for preventing depression in children

Conditions: Depression

Summary: this study will determine the effectiveness of cognitive behavioral therapy (cbt) versus educational treatment in preventing depression in the children of parents with a history of depression.

depression is a serious condition that can affect a person's work, relationships, and quality of life. studies have shown that children of depressed parents are at a higher risk for developing depression than those whose parents have not experienced depression. safe and effective treatments that can help prevent children of depressed parents from becoming depressed are needed. this study will compare cbt to depression education to determine which is more effective in preventing depression in the children of depressed parents. families will be randomly assigned to receive weekly sessions of either cbt or depression education for 12 weeks. parents in the cbt group will be taught skills to more effectively raise their children and to better manage their depressive symptoms; their children will be taught skills to cope with the stress of their parents' depression. families in the education group will be informed about the ways that depression can affect individuals with depression and their families. study visits will occur at study entry and at week 12. several follow-up visits will occur for up to 2 years after the interventional part of the study. at each visit, a clinician will make direct observations of the depressed parent's interaction with his or her children. in addition, families will be interviewed and will complete questionnaires about the parent's depressive symptoms and family interaction.

Eligibility criteria:
inclusion criteria for participating families: * families with at least one parent with a history of depression during the life of his or her child * families with at least one child between the age of 10 and 15 * parent or guardian willing to provide informed consent for participating children exclusion criteria for all participants: * parent with bipolar disorder or schizophrenia * child with conduct disorder or pervasive developmental disorder

Keywords: parents child stress cbt
the sun protection effect and efficacy in treatment of sunburn using topical corticosteroids.

Conditions: Sunburn

Summary: the purpose of the study is to evaluate the sun protection effect and efficacy in treatment of sunburn using topical corticosteroids in a randomised controlled and investigator blinded trial.


Eligibility criteria:
inclusion criteria: * 18 years or older, healthy, fair skinned (skin type i-iii) exclusion criteria: * pregnant or lactating women.in treatment with corticosteroids.

Keywords: sunburn corticosteroids
enhancing physical activity and weight reduction through smartcare and financial incentives

Conditions: Obesity

Summary: the investigators are planning to conduct a pilot rct of young obese population to evaluate the effect of smartcare with or without financial incentives for 12 weeks. participants will be randomly assigned to a three-arm of control, smartcare, and smartcare plus financial incentives group.

to test the feasibility and potential impact of smartcare with or without financial incentives, the study employed a three-arm, open label randomized controlled trial design: control, smartcare, and smartcare plus financial incentives. the investigators hypothesized that the 'smartcare + financial incentive' arm will show the greatest change in outcomes, followed by the 'smartcare' only arm, and lastly the control arm. specific aims of the study are as follows: * to quantify the effectiveness of a 'smartcare' intervention to promote physical activity and reduce weight over a 12 week period. * to quantify the incremental effectiveness of adding financial incentives to 'smartcare' intervention

Eligibility criteria:
inclusion criteria: 1. male students aged between 19 to 45; 2. body mass index ≥ 27; 3. smartphone user (either android or iphone); 4. able and willing to attend a four pre-specified visit during the study period. exclusion criteria: 1. any treatment involving pharmacotherapy, procedure, or surgery; 2. use of any activity tracker device during the last three months. 3. those who answered positively to any physical activity readiness questionnaire (par-q) question were also excluded.
level of agreement of intraocular lens power measurements between iolmaster and verion

Conditions: Cataract

Summary: primary objective of this study is to evaluate the level of agreement of two keratometry modules, the iolmaster and the verion reference unit, in terms of keratometric values and iol power calculation.

participants were enrolled from the cataract \& presbyopia service of the university general hospital of alexandroupolis in a consecutive-if-eligible basis. apart from keratometric values, iol power calculations will be compared for 8 iol models (acrysof sn60wf, sn60at, sn6atx, tfnt00, tfntx0, sv25t0, sv25tx and tecnis zcb00) using 4 formulas (srk/t, holladay 1, hoffer q and haigis).

Eligibility criteria:
inclusion criteria: * senile cataract exclusion criteria: * former incisional surgery, * corneal diseases, * dry-eye-disease, * glaucoma drops, * inability to obtain accurate measurements.

Keywords: cataract surgery verion image-guided system iolmaster iol calculation keratometry corneal power toric iol
scale kids: research study to look at how well a new medicine is at lowering weight in children with obesity

Conditions: Obesity

Summary: the study looks at how liraglutide works on participant's body weight. researchers will look at how liraglutide can help children with obesity to lose weight. they will look at how much weight the children will lose, and if there are any side effects. participants will either get liraglutide or placebo. which treatment the participants get is decided by chance. liraglutide is a new medicine for children, but it can already be prescribed by doctors to adults with overweight or obesity. the participant will get 1 injection every day. in addition to taking the medicine, the participants will have talks with the study staff about healthy food choices, how they can be more physically active and what can be done to help the participants to lose weight. the study will last for about 96 weeks (almost 2 years). the participants will have 18 clinic visits and 10 phone or video calls with the study doctor/staff. participant will have blood samples taken, have 1 test to check the heart, 1 hand x-ray taken and must fill in a diary between some of the visits.


Eligibility criteria:
inclusion criteria: * informed consent of parent(s) or legally acceptable representative of subject and child assent, as age-appropriate, obtained before any trial-related activities. trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial * male or female, aged 6 to below 12 years at the time of signing informed consent * tanner stage 1-5 pubertal development at the time of signing informed consent * bmi above or equal to 95th percentile, on gender and age-specific growth charts (cdc.gov) * history of failing to lose sufficient weight with lifestyle modification as judged by the investigator for subjects with type 2 diabetes at screening the following inclusion criterion apply in addition: - hemoglobin a1c (hba1c) below or equal to 10.0 percent (86 mmol/mol) as measured by central laboratory at screening exclusion criteria: * a self-reported (or by parent(s)/lar (legally acceptable representative) where applicable) change in body weight above 5 kg (11 lbs) within 90 days before screening irrespective of medical records * treatment with any medication for the indication of obesity within the past 90 days before screening * type 1 diabetes * subjects with secondary causes of obesity (for example hypothalamic, monogenic or endocrine causes)
effect of postural reeducation versus pelvic floor muscle training on stress urinary incontinence

Conditions: Stress Urinary Incontinence

Summary: the purpose of the study is to evaluate the effects of postural reeducation compared to pelvic floor muscle training on urinary incontinence (ui) symptoms, the impact of ui, and quality of life (qol) in women experiencing stress urinary incontinence (sui)

the study is designed as a randomized- controlled trial. it will be carried out on women suffering from stress urinary incontinence referred after urology consultations to the physiotherapy clinic in soad kafafy hospital. ui, particularly sui, affects up to 28% of the population and occurs during activities like coughing or sneezing due to inadequate urethral closure pressure. the pelvic floor muscles play a critical role in supporting pelvic organs and maintaining continence. pelvic floor dysfunction is a significant contributor to sui. postural dysfunction can increase mechanical stress and lead to pelvic floor dysfunction. postural re-education techniques aim to correct imbalances and improve pelvic floor muscle activity, potentially alleviating sui symptoms by restoring muscle efficiency and enhancing continence.

Eligibility criteria:
inclusion criteria: * fifty females with stress urinary incontinence. * age of 30-40 years. * body mass index (bmi) \> 30 kg/m2 exclusion criteria: * genital prolapse grade 3 or 4 based on pelvic organ prolapse quantification classification (pop-q). * overactive bladder (oab) * functional impairment (barthel scale \<85 points). * neurological or cognitive impairment (mini mental examination \<24 points). * any other type of urinary incontinence. * pregnancy. * history of spinal, hip, knee or foot surgery, pelvic and abdominal surgery (including cesarean section) * smoking, chronic cough, history of respiratory diseases, osteoporosis (self-reported).
platelet rich plasma combined with human umbilical cord mesenchymal stem cells for stage 3 and 4 stress injury

Conditions: Pressure Injuries - Stage 3; Pressure Injuries - Stage 4

Summary: this study is an open-label, single-center trial which aim to evaluate of efficacy and safety of human umbilical cord-derived mesenchymal stem cells (huc-mscs) combined with platelet-rich plasma (prp) in stage 3 and 4 stress injury.

the 2019 edition of the international guidelines for clinical prevention and treatment of stress injury states that stress injury, as a globally prevalent health issue, significantly reduces the quality of life for patients and their families, increases economic burden, and leads to significant expenditure on medical resources. in recent years, the incidence and mortality rate of pressure injuries in hospitalized patients have been increasing year by year. therefore, there is an urgent need to find a more effective treatment method for pressure injuries in clinical practice. human umbilical cord mesenchymal stem cells (humscs) have immunomodulatory and anti-inflammatory effects. platelet rich plasma (prp) can also secrete various nutritional factors, which can effectively promote wound healing. therefore, the combination of the two may be a more effective treatment method for pressure injuries. at present, there are few reports on the combination of prp and humscs for the treatment of pressure injury. in this study, the investigators aim to evaluate the effectiveness and safety of prp combined with humscs for stage 3 and 4 pressure injuries, in order to promote their clinical application.

Eligibility criteria:
inclusion criteria: * 18-80 years old, regardless of gender; * patients with stage 3 and stage 4 pressure injuries (according to national pressure ulcer advisory panel (npuap)/european pressure ulcer advisory panel (epuap) classification system for pressure ulcers); * there were no complications affecting the wound healing; * after through debridement for the first time, the wound volume meets the requirement of "10-100cm3"; platelet count before treatment 100\~300×109/l; * the patient voluntarily participates and signs an informed consent form. exclusion criteria: * individuals with coagulation dysfunction or hemorrhagic diseases; * people with skin diseases, diabetes and immune diseases; * individuals with mental or psychological disorders; * individuals with allergies to multiple drugs; * pregnant or lactating women; * those who need to take medication that affects platelet and coagulation function for a long time or in the near future, but have not stopped taking medication within the past week.

Keywords: mesenchymal stem cells platelet rich plasma pressure injuries
effect of antioxidant food supplement on sperm proteomic structure and semen parameters

Conditions: Asthenozoospermia

Summary: infertility is defined as the inability to become pregnant despite 12 months of regular and unprotected intercourse. male factors include defects in sperm concentration, morphology and motility, among which low sperm motility (asthenozoospermia) is one of the most common types of male infertility and affects approximately 40% of all cases. it has become clear that protein defects in spermatozoa and semen can cause fertilization failure by affecting sperm motility, and it is necessary to define proteins and related pathways precisely because they have an important role in the treatment phase. increasing evidence shows that free oxygen radicals that occur as a result of oxidative stress (os) play a very important role in the etiology of male infertility. a systematic review including 29 studies (19 randomized clinical trials and 10 prospective studies) examined the effect of antioxidant food supplementation and reported a positive effect on baseline semen parameters, advanced sperm function, outcomes of assisted reproductive therapy, and live birth rate. conversely, few studies have failed to confirm any positive effect of antioxidant therapy and even report a negative effect on male fertility. therefore, there is no clear consensus on the clinical efficacy of antioxidant therapy yet. since the pathogenesis has not yet been clearly demonstrated, treatments are not based on evidence, but based on clinical experience. our aim was to randomly divide infertile male patients who applied to our clinic with the complaint of infertility and found asthenozoospermia (restricted sperm motility) in their semen analysis into two arms and examine the effects of antioxidant food supplementation on sperm motility and proteomic structure with a placebo-comparative, prospective, double-blind study (lc-ms/ms). analysis) is to reveal the metabolic pathways that may lead to restriction of movement. the effect of antioxidant food support on sperm parameters and free oxygen radical levels in the control spermiogram after 3 (three) months of treatment to be given to the patients will be measured by elisa method and compared with pre-treatment values.


Eligibility criteria:
inclusion criteria: 1. being in the age range of 20-40 2. be infertile ( 12 months intercourse without any contraception) 3. due to infertility, you should apply to us and have a spermiogram detection of asthenozoospermia 4. patients whose spouses have normal gynecological examinations 5. patients with normal physical examinations 6. patients with normal hormonal values (fsh, lh,prl,testosterone,estrogen) - exclusion criteria: 1. previous treatment for infertility 2. previously due to infertility or for any reason take antioxidant food supplements 3. surgery or physical examination due to varicocele detection of varicocele 4. detection of endocrine disorder (defect in serum blends) 5. smokers and alcohol addiction 6. detection of infection in the genital tract 7. having a chronic illness -

Keywords: infertility antioxidant proteomics
a single-dose study to investigate the pharmacokinetics of intravenous fep-taz in patients with renal impairment

Conditions: Renal Impairment

Summary: this is a phase 1, open label, single-dose, pharmacokinetic study to be conducted in male and female subjects with normal and impaired renal function. the study will be composed of five groups of patients with mild (6 patients), moderate (6 patients), severe (6 patients) renal impairment, end stage renal disease patients on hemodialysis (6 patients) and their respective matched controls in 1:1 ratio (24 healthy subjects with normal renal function).


Eligibility criteria:
inclusion criteria: -patients with renal impairment: mild, moderate, severe and patients on hemodialysis) that has been stable or * healthy subjects: * have normal renal function * no evidence of any disease or condition that may affect pharmacokinetics of fep-taz. exclusion criteria: * evidence of hepatorenal or nephritic syndrome * any clinically significant abnormal findings on medical history, physical examination,or clinical laboratory tests (other than those associated with controlled diabetes,hypertension, hypercholesterolemia, dyslipidemia, or renal impairment or related or causative diseases)
a study assessing the health-related quality of life (hrqol) in participants with relapsed and/or refractory multiple myeloma (rrmm) with triple class exposure

Conditions: Multiple Myeloma

Summary: the purpose of this observational study is to assess hrqol in relapsed and/or refractory multiple myeloma (rrmm) participants who have previously received a proteasome inhibitor, an immunomodulatory agent, and an anti-cd38 antibody.


Eligibility criteria:
inclusion criteria: * must have sufficient command of the japanese language to understand the study instructions and requirements * must be a resident of japan * must have received prior treatment with: 1. a proteasome inhibitor, 2. an immunomodulatory agent, and 3. an anti-cd38 antibody subjects must be either 2-4 months, 5-7 months, or 8-11 months post triple class therapy exposure at time of consent * subject must be diagnosed with multiple myeloma exclusion criteria: * participants enrolled in a clinical trial that includes at least one novel/ experimental agent at the point of questionnaire completion other protocol-defined inclusion/exclusion criteria apply.

Keywords: multiple myeloma hrqol relapsed refractory outcomes
influence of sit muscle strength training and game on elderly

Conditions: Aging; Physical Disability; Dementia; Elderly

Summary: objective: the study aims to understand the physical function, body composition, mental state, behavior, depression, and life quality change of the elderly in a long-term care before and after the intervention. four interventional activities are sitting strength training, games, sitting strength training with games, and health education.

expected results: (1) the program will facilitate arrange activities that are beneficial to the body and mind, activate bodily functions, and promote the quality of life of the elderly in taiwan. (2) the program can compare the effectiveness of different trainings for the elderly and provide a reference for future implementation planning. (3) evidence of the empirical study of this program can provide future comparisons with other domestic and foreign studies.

Eligibility criteria:
1.inclusion criteria: 1. elderly persons between the age of 60 and 100 who take long-term care of the relevant units do not have limited sports 2. stable condition with sufficient physical strength: at least one hour sitting in the wheelchair or bed edge. 3. subjects in the past month tended to live in static state (less than 150 minutes of exercise time per week). 2.exclusion criteria: 1. serious illness / unstable status (judged by medical staff), such as serious cardiopulmonary diseases, severe malignant tumor (assessment from medical personnel), severe malnutrition (mini nutrition assessment scale 0-7 points). 2. unstable weight over the past six months (\> ± 4 kg).
prospective cohort study for stereotactic arhythmia radioablation (star) of refractory ventricular tachycardia

Conditions: Refractory Ventricular Tachycardia

Summary: this is a multicenter, interventional study. the study will enroll patients that fulfill the inclusion criteria over a 33-month period. considering the small number of patients who will meet the study criteria, it is also possible to include retrospective patients who already underwent star (for instance, as part of a compassionate program) if they meet all the inclusion and exclusion criteria as well as the treatment planning standardized requirements and sign their consent to this trial. all patients prospectively enrolled will undergo a flow of investigations following a standardized approach. icd programming will be standardized.


Eligibility criteria:
inclusion criteria: 1. structural heart disease (shd) defined as left ventricular dysfunction (lvef \< 55%), or right ventricular dysfunction (fac \<35%) or presence of ventricular scar, pathological hypertrophy, wall bulging or inflammatory conditions. 2. optimized medical treatment for the underlying shd 3. icd or crt-d recipient 4. ≥ 1 episodes of sustained or treated (with either anti-tachycardia pacing or shock, internal or external) monomorphic vt (mmvt) resistant to at least one invasive vt ablation attempt, unless contraindicated or deemed at high risk. reason for lack of ablation must be specified exclusion criteria: 1. age \ 85 years. 2. inability to provide informed consent. 3. acute myocardial infarction or recent primary coronary intervention or cardiac surgery (\<3 months) 4. primary electrical disease (e.g. long qt syndrome, short qt syndrome, catecholaminergic polymorphic ventricular tachycardia, brugada syndrome). 5. reversible and/or treatable cause of vt (e.g., drug-induced or intoxication) 6. icd electrode malfunction or icd readings outside reference range 7. pregnancy or breast feeding 8. patients with polymorphic vt/vf